INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Unicycive Therapeutics and its officers or directors following a significant stock price drop after the FDA issued a Complete Response Letter for its New Drug Application [1][3]. Group 1: Company Overview - Unicycive Therapeutics, Inc. is a company listed on NASDAQ under the ticker UNCY [1]. - The company recently faced regulatory challenges when the FDA issued a Complete Response Letter for its New Drug Application for OLC, intended to treat hyperphosphatemia in patients with chronic kidney disease on dialysis [3]. Group 2: Regulatory Issues - The FDA's Complete Response Letter was issued due to deficiencies found at a third-party manufacturing vendor associated with Unicycive's contract development and manufacturing organization [3]. - Following the announcement of the FDA's decision, Unicycive's stock price fell by $2.03 per share, representing a decline of 29.85%, closing at $4.77 per share on June 30, 2025 [3]. Group 3: Legal Actions - Pomerantz LLP is actively seeking claims from investors of Unicycive regarding potential securities fraud or other unlawful practices [1]. - Investors are encouraged to contact Pomerantz LLP for participation in the investigation [1].